Evaluation of the fragility of pivotal trials used to support FDA approval for plaque psoriasis: Supplementary Figures and Tables
Published: 30 August 2020| Version 1 | DOI: 10.17632/5sxhn6hn6g.1
Contributors:
Sophia Shalhout, Romi Bloom, Lynn Drake, David Michael MillerDescription
Supplementary Tables 1- 4, Supplementary Figures 1- 3
Files
Institutions
- Harvard Medical School
- Massachusetts General Hospital Cancer Center
Categories
Therapeutics, Randomized Controlled Trial, Psoriasis